rmtОбщая реаниматологияGeneral Reanimatology1813-97792411-7110FSBI "SRIGR" RAMS10.15360/1813-9779-2021-3-2-0rmt-2075Research ArticleКЛИНИЧЕСКИЕ И ЭКСПЕРИМЕНТАЛЬНЫЕ ИССЛЕДОВАНИЯCLINICAL AND EXPERIMENTAL STUDIESБиомаркеры повреждения структур аэрогематического барьера при COVID-19Biomarkers of Air-Blood Barrier Damage In COVID-19ХаджиеваМ. Б.KhadzhievaM. B.

Марьям Борисовна Хаджиева

107031, Москва, ул. Петровка, д. 25, стр. 2; 117997, Москва, ул. Саморы Машела, д. 1; ; 119991, Москва, ул. Губкина, д. 3

Maryam B. Khadzhieva

25 Petrovka Str., Bldg. 2, 107031 Moscow; 1 Samora Mashela Str., GSP-7, 117997 Moscow; 3    Gubkin Str., 119991 Moscow

mkhadzhieva@fnkcrr.ruГрачеваА. С.GrachevaA. S.

107031, Москва, ул. Петровка, д. 25, стр. 2; 119991, Москва, ул. Губкина, д. 3

Alesya S. Gracheva

25 Petrovka Str., Bldg. 2, 107031 Moscow; 3 Gubkin Str., 119991 Moscow

ЕршовА. В.ErshovA. V.

107031, Москва, ул. Петровка, д. 25, стр. 2

Anton V Ershov

25 Petrovka Str., Bldg. 2, 107031 Moscow

ЧурсиноваЮ. В.ChursinovaYu. V.

129110, Москва, ул. Щепкина, д. 61/2

Yulia V. Chursinova

61/2 Shchepkin Str., 129110 Moscow

СтепановВ. А.StepanovV. A.

129110, Москва, ул. Щепкина, д. 61/2

Vadim A. Stepanov

61/2 Shchepkin Str., 129110 Moscow

АвдейкинаЛ. С.AvdeikinaL. S.

142160, Москва, поселение Вороновское, поселок ЛМС

Lyudmila S. Avdeikina

LMS village Voronovskoe settlement, 142160 Moscow

ГребенчиковО. А.GrebenchikovO. A.

107031, Москва, ул. Петровка, д. 25, стр. 2

Oleg A. Grebenchikov

25 Petrovka Str., Bldg. 2, 107031 Moscow

БабкинаА. С.BabkinaA. S.

107031, Москва, ул. Петровка, д. 25, стр. 2

Anastasia S. Babkina

25 Petrovka Str., Bldg. 2, 107031 Moscow

ШабановА. К.ShabanovA. K.

107031, Москва, ул. Петровка, д. 25, стр. 2; 129010, Москва, Большая Сухаревская площадь, д. 3

Aslan K. Shabanov

25 Petrovka Str., Bldg. 2, 107031 Moscow; 3 Bolshaya Sukharevskaya Square, 129090 Moscow

ТутельянА. В.TutelyanA. V.

111123, Москва, ул. Новогиреевская, д. 3а

Alexey V Tutelyan

3a Novogireevskaya Str., 111123 Moscow

ПетриковС. С.PetrikovS. S.

129010, Москва, Большая Сухаревская площадь, д. 3

Sergey S. Petrikov

3 Bolshaya Sukharevskaya Square, 129090 Moscow

КузовлевА. Н.KuzovlevA. N.

107031, Москва, ул. Петровка, д. 25, стр. 2; 

Artem N. Kuzovlev

25 Petrovka Str., Bldg. 2, 107031 Moscow

НИИ общей реаниматологии им. В. А. Неговского ФНКЦ РР; Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России; Институт общей генетики им. Н.И. Вавилова, РАНРоссияV.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; D. Rogachev Federal Scientific Clinical Centre of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia; N.I. Vavilov Institute of General Genetics, Russian Academy of SciencesRussian FederationНИИ общей реаниматологии им. В. А. Неговского ФНКЦ РР; Институт общей генетики им. Н.И. Вавилова, РАНРоссияV.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; N.I. Vavilov Institute of General Genetics, Russian Academy of SciencesRussian FederationНИИ общей реаниматологии им. В.А. Неговского ФНКЦ РРРоссияV.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and RehabilitologyRussian FederationМосковский областной научно-исследовательский клинический институт им. М.Ф. ВладимирскогоРоссияM.F. Vladimirsky Moscow Regional Research Clinical InstituteRussian FederationВороновская больница ДЗМРоссияVoronovskaya Hospital, Moscow City Health DepartmentRussian FederationНИИ общей реаниматологии им. В. А. Неговского ФНКЦ РРРоссияV.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and RehabilitologyRussian FederationНИИ общей реаниматологии им. В. А. Неговского ФНКЦ РР; НИИ скорой помощи им. Н. В. Склифосовского ДЗМРоссияV.A. Negovsky Research Institute of General Reanimatology, Federal Research and Clinical Center of Intensive Care Medicine and Rehabilitology; N.V. Sklifosovsky Research Institute of Emergency MedicineRussian FederationЦентральный НИИ эпидемиологии РоспотребнадзораРоссияCentral Research Institute of Epidemiology, RospotrebnadzorRussian FederationНИИ скорой помощи им. Н.В. Склифосовского ДЗМРоссияN.V. Sklifosovsky Research Institute of Emergency MedicineRussian Federation2021010720211731631Copyright © Хаджиева М.Б., Грачева А.С., Ершов А.В., Чурсинова Ю.В., Степанов В.А., Авдейкина Л.С., Гребенчиков О.А., Бабкина А.С., Шабанов А.К., Тутельян А.В., Петриков С.С., Кузовлев А.Н., 20212021Хаджиева М.Б., Грачева А.С., Ершов А.В., Чурсинова Ю.В., Степанов В.А., Авдейкина Л.С., Гребенчиков О.А., Бабкина А.С., Шабанов А.К., Тутельян А.В., Петриков С.С., Кузовлев А.Н.Khadzhieva M.B., Gracheva A.S., Ershov A.V., Chursinova Y.V., Stepanov V.A., Avdeikina L.S., Grebenchikov O.A., Babkina A.S., Shabanov A.K., Tutelyan A.V., Petrikov S.S., Kuzovlev A.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.reanimatology.com/rmt/article/view/2075

Поиск чувствительных и специфичных маркеров, позволяющих своевременно выявить пациентов с новой коронавирусной инфекцией COVID-19 с высоким риском смерти, является обязательным условием для обеспечения их своевременного лечения.

Цель исследования — оценка ассоциации молекулярных биомаркеров повреждения структур аэрогематического барьера (сурфактантные белки SP-A и SP-D и белок клеток Клара CC16) с исходом заболевания пациентов с COVID-19.

Материалы и методы

Материалы и методы. Выборку из 109 человек ретроспективно разделили на две группы; 1-ю группу составили пациенты, выписанные из ОРИТ в удовлетворительном состоянии (и=90), 2-ю группу сформировали из пациентов с летальным исходом (и=19). Ассоциацию исхода заболевания и содержания SP-A, SP-D и CC16 в сыворотке крови, клинических и лабораторных данных выявляли с учетом дня забора биоматериала с момента появления первых симптомов COVID-19.

Результаты

Результаты. У пациентов с летальным исходом по сравнению с пациентами, выписанными из ОРИТ в удовлетворительном состоянии, установили повышенную концентрацию SP-A с 1-х по 10-е сутки и сниженную — CC16 с 11-х по 20-е сутки появления первых симптомов, для SP-D — статистически значимых различий не обнаружили.

Заключение

Заключение. По результатам настоящего исследования сурфактантный белок SP-A и белок клеток Клара CC16 ассоциированы с летальным исходом от COVID-19.

The search for sensitive and specific markers enabling timely identification of patients with a life-threatening novel coronavirus infection (COVID-19) is important for a successful treatment.

The aim of the study was to examine the association of molecular biomarkers of air-blood barrier damage, surfactant proteins SP-A and SP-D and Club cell protein CC16, with the outcome of patients with COVID-19.

Materials and methods

Materials and methods. A cohort of 109 patients diagnosed with COVID-19 was retrospectively divided into two groups. Group 1 comprised survivor patients discharged from the ICU (w=90). Group 2 included the patients who did not survive (w=19). Association of disease outcome and SP-A, SP-D, and CC16 levels in blood serum, clinical, and laboratory data were examined taking into account the day of illness at the time of biomaterial collection.

Results

Results. The non-survivors had higher SP-A (from days 1 to 10 of symptoms onset) and lower CC16 (from days 11 to 20 of symptoms onset) levels vs survivors discharged from ICU. No significant differences in SP-D levels between the groups were found.

Conclusion

Conclusion. According to the study results, the surfactant protein SP-A and Club cell protein CC16 are associated with increased COVID-19 mortality.

сурфактантный белок SP-Aсурфактантный белок SP-Dбелок клеток Клара CC16COVID-19surfactant protein SP-Asurfactant protein SP-DClub cell protein CC16COVID-19Исследование выполнено при финансовой поддержке РФФИ в рамках научного проекта № 20-04-60352The reported study was funded by RFBR, project number 20-04-60352.ReferencesMason R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020; 55(4):2000607. DOI: 10.1183/13993003.00607-2020. PMID: 32269085Mason R.J. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020; 55 (4): 2000607. DOI: 10.1183/13993003.00607-2020. PMID: 32269085Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., Peng Z., Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020; 127:104364. DOI: 10.1016/j.jcv.2020.104364. PMID: 32311650Zhang G., Hu C., Luo L., Fang F., Chen Y., Li J., PengZ., Pan H. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020; 127: 104364. DOI: 10.1016/j.jcv.2020.104364. PMID: 32311650Ciceri F., Castagna A., Rovere-Querini P., De Cobelli F., Ruggeri A., Galli L., Conte C., De Lorenzo R., Poli A., Ambrosio A., Signorelli C., Bossi E., Fazio M., Tresoldi C., Colombo S., Monti G., Fominskiy E., Franchini S., Spessot M., Martinenghi C., Carlucci M., Beretta L., Scandroglio A.M., Clementi M., Locatelli M., Tresoldi M., Scarpellini P. Martino G., Bosi E., Dagna L., Lazzarin A., Landoni G., Zangrillo A. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020; 217:108509. DOI: 10.1016/j.clim.2020.108509. PMID: 32535188Ciceri F., Castagna A., Rovere-Querini P, De Cobelli F., Ruggeri A., Galli L., Conte C., De Lorenzo R., Poli A., Ambrosio A., Signorelli C., Bossi E., Fazio M., Tresoldi C., Colombo S., Monti G., Fominskiy E., Franchini S., Spessot M., Martinenghi C., Carlucci M., Beretta L., Scandroglio A.M., Clementi M., Locatelli M., Tresoldi M., Scarpellini P, Martino G., Bosi E., Dagna L., Lazzarin A., Landoni G., Zangrillo A. Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clin Immunol. 2020; 217: 108509. DOI: 10.1016/j.clim.2020.108509. PMID: 32535188Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., Iotti G., Latronico N., Lorini L., Merler S., Natalini G., Piatti A., Ranieri M.V., Scandroglio A.M., Storti E., Cecconi M., Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. DOI: 10.1001/jama.2020.5394. PMID: 32250385Grasselli G., Zangrillo A., Zanella A., Antonelli M., Cabrini L., Castelli A., Cereda D., Coluccello A., Foti G., Fumagalli R., Iotti G., Latronico N., Lorini L. , Merler S., Natalini G., Piatti A., Ranieri M.V., Scandroglio A.M., Storti E., Cecconi M., Pesenti A; COVID-19 Lombardy ICU Network. Baseline Characteristics and Outcomes of1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323 (16): 1574-1581. DOI: 10.1001/jama.2020.5394. PMID: 32250385Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. DOI: 10.1016/j.jaut.2020.102433. PMID: 32113704Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020; 109: 102433. DOI: 10.1016/j.jaut.2020.102433. PMID: 32113704Забозлаев Ф.Г., Кравченко Э.В., Галлямова А.Р., Летуновский Н.Н. Патологическая анатомия легких при новой коронавирусной инфекции (COVID-19). Предварительный анализ аутопсийных исследований. Клиническая практика. 2020; 11(2):21-37. DOI: 10.17816/clinpract34849.Zabozlaev F.G., Kravchenko E.V., Gallyamova A.R., Letunovsky N.N. Pulmonary pathology of the new coronavirus disease (COVID-19). The preliminary analysis of post-mortem findings. Journal of Clinical Practice. 2020; 11 (2): 21-37 [In Russ.]. DOI: 10.17816/clinpract34849Белобородова Н.В., Зуев Е.В., Замятин М.Н., Гусаров В.Г. Этиотропная терапия COVID-19: критический анализ и перспективы. Общая реаниматология. 2020; 16 (6): 65–90. DOI: 10.15360/1813-9779-2020-4-0-1.Beloborodova N.V., Zuev E.V., Zamyatin M.N., Gusarov VG. Causal Therapy of COVID-19: Critical Review and Prospects. Obshchaya Rea-nimatologiya= GeneralReanimatology. 2020; 16 (6): 65-90 [In Russ.]. DOI: 10.15360/1813-9779-2020-4-0-1Struyf T., Deeks J.J., Dinnes J., Takwoingi Y., Davenport C., Leeflang M.M., Spijker R., Hooft L., Emperador D., Dittrich S., Domen J., Horn S.R.A., Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020; 7(7):CD013665. DOI: 10.1002/14651858.CD013665. Update in: Cochrane Database Syst Rev. 2021; 2:CD013665. PMID: 32633856Struyf T., Deeks J.J., Dinnes J., Takwoingi Y., Davenport C., Leeflang M. M., Spijker R., Hooft L., Emperador D., Dittrich S., Domen J., Horn S.R.A., Van den Bruel A; Cochrane COVID-19 Diagnostic Test Accuracy Group. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19 disease. Cochrane Database Syst Rev. 2020; 7 (7): CD013665. DOI: 10.1002/14651858.CD013665. Update in: Cochrane Database Syst Rev. 2021; 2: CD013665. PMID: 32633856Li X., Xu S., Yu M., Wang K., Tao Y., Zhou Y., Shi J., Zhou M., Wu B., Yang Z., Zhang C., Yue J., Zhang Z., Renz H., Liu X., Xie J., Xie M., Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118. DOI: 10.1016/j.jaci.2020.04.006. PMID: 32294485Li X., Xu S., Yu M., WangK., Tao Y., Zhou Y., Shi J., Zhou M., Wu B., Yang Z., Zhang C., Yue J., Zhang Z., Renz H., Liu X., Xie J., Xie M., Zhao J. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020; 146 (1): 110-118. DOI: 10.1016/j.jaci.2020.04.006. PMID: 32294485Nardelli P., Landoni G. COVID-19-Related Thromboinflammatory Status: MicroCLOTS and Beyond. Obshchaya Reanimatologiya= General Reanimatology. 2020; 16 (3): 14–15. DOI: 10.15360/1813-9779-2020-3-0-2Nardelli P, Landoni G. COVID-19-Related Thromboinflammatory Status: MicroCLOTS and Beyond. Obshchaya Reanimatologiya = Ob-shchaya Reanimatologiya= General Reanimatology. 2020; 16 (3): 1415. DOI: 10.15360/1813-9779-2020-3-0-2 [In Russ.]Han S., Mallampalli R.K. The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections. Ann Am Thorac Soc. 2015; 12(5):765-774. DOI:10.1513/AnnalsATS.201411-507FR. PMID: 25742123Han S., Mallampalli R.K. The Role of Surfactant in Lung Disease and Host Defense against Pulmonary Infections. Ann Am Thorac Soc. 2015; 12 (5): 765-774. DOI: 10.1513/AnnalsATS.201411-507FR. PMID: 25742123Takano H. Pulmonary surfactant itself must be a strong defender against SARS-CoV2. Med Hypotheses. 2020; 144:110020. DOI:10.1016/j.mehy.2020.110020. PMID: 32590326Takano H. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2. Med Hypotheses. 2020; 144: 110020. DOI: 10.1016/j.mehy.2020.110020. PMID: 32590326Naha N, Muhamed JCJ, Pagdhune A, Sarkar B, Sarkar K. Club cell protein 16 as a biomarker for early detection of silicosis. Indian J Med Res. 2020;151(4):319-325. DOI:10.4103/ijmr.IJMR_1799_18. PMID: 32461395Naha N., Muhamed J.C.J., Pagdhune A., Sarkar B., Sarkar K Club cell protein 16 as a biomarker for early detection of silicosis. Indian J Med Res. 2020; 151 (4): 319-325. DOI: 10.4103/ijmr.IJMR_1799_18. PMID: 32461395Almuntashiri S, Zhu Y, Han Y, Wang X, Somanath PR, Zhang D. Club Cell Secreted Protein CC16: Potential Applications in Prognosis and Therapy for Pulmonary Diseases. J Clin Med. 2020; 9(12):4039. DOI:10.3390/jcm9124039. PMID: 33327505Almuntashiri S., Zhu Y., Han Y., Wang X., Somanath P.R., Zhang D. Club Cell Secreted Protein CC16: Potential Applications in Prognosis and Therapy for Pulmonary Diseases. J Clin Med. 2020; 9 (12): 4039. DOI: 10.3390/jcm9124039. PMID: 33327505Кузовлев А.Н., Мороз В.В. Нозокомиальная пневмония — принципы ранней диагностики и профилактики. Вестник интенсивной терапии имени А.И. Салтанова. 2019;2:40–7. DOI: 10.21320/1818-474X-2019-2-40-47.Kuzovlev A.N., Moroz V.V. Nosocomial pneumonia — principles of early diagnosis and prevention. Alexander Saltanov Bulletin of Intensive Care. 2019; 2: 40-7 [In Russ.]. DOI: 10.21320/1818-474X-2019-2-40-47Hasegawa Y., Takahashi M., Ariki S., Asakawa D., Tajiri M., Wada Y., Yamaguchi Y., Nishitani C., Takamiya R., Saito A., Uehara Y., Hashimoto J., Kurimura Y., Takahashi H., Kuroki Y. Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling. Oncogene. 2015; 34(7):838-45. DOI: 10.1038/onc.2014.20. PMID: 24608429Hasegawa Y., Takahashi M., Ariki S., Asakawa D., Tajiri M., Wada Y., Yamaguchi Y., Nishitani C., Takamiya R., Saito A., Uehara Y., Hashi-moto J., Kurimura Y., Takahashi H., Kuroki Y. Surfactant protein D suppresses lung cancer progression by downregulation of epidermal growth factor signaling. Oncogene. 2015; 34 (7): 838-45. DOI: 10.1038/onc.2014.20. PMID: 24608429Yoshikawa T., Otsuka M., Chiba H, Ikeda K, Mori Y, Umeda Y, Nishikiori H, Kuronuma K, Takahashi H. Surfactant protein A as a biomarker of outcomes of antifibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 31;20(1):27. DOI: 10.1186/s12890-020-1060-y. Erratum in: BMC Pulm Med. 2020 May 7;20(1):131. PMID: 32005219Yoshikawa T., Otsuka M., Chiba H., Ikeda K., Mori Y., Umeda Y., Nishi-kiori H., Kuronuma K., Takahashi H. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 31; 20 (1): 27. DOI: 10.1186/s12890-020-1060-y. Erratum in: BMC Pulm Med. 2020 May 7; 20 (1): 131. PMID: 32005219Кузовлев А.Н., Мороз В.В., Голубев А.М., Половников С.Г., Смелая Т.В. Диагностика острого респираторного дистресс-синдрома при нозокомиальной пневмонии. Общая реаниматология. 2009;5(6):5. DOI: 10.15360/1813-9779-2009-6-5.KuzovlevA.N., MorozV.V., GolubevA.M., PolovnikovS.G., Smelaya T.V. Diagnosis of Acute Respiratory Distress Syndrome in Nosocomial Pneumonia. Obshchaya Reanimatologiya= General Reanimatology. 2009; 5 (6): 5. [In Russ.] DOI: 10.15360/1813-9779-2009-6-5Gallo Marin B., Aghagoli G., Lavine K., Yang L., Siff E.J., Chiang S.S., SalazarMather T.P., Dumenco L., Savaria M.C., Aung S.N., Flanigan T., Michelow I.C. Predictors of COVID-19 severity: A literature review. Rev Med Virol. 2021; 31(1):1-10. DOI: 10.1002/rmv.2146. PMID: 32845042Gallo Marin B., Aghagoli G., LavineK., YangL., Siff E.J., ChiangS.S., Sa-lazar-Mather T.P., Dumenco L., Savaria M.C., Aung S.N., Flanigan T., Michelow I.C. Predictors of COVID-19 severity: A literature review. Rev MedVirol. 2021; 31 (1): 1-10. DOI: 10.1002/rmv.2146. PMID: 32845042Chen X., Peng F., Zhou X., Zhu J., Chen X., Gong Y., Shupeng W., Niu W. Predicting severe or critical symptoms in hospitalized patients with COVID-19 from Yichang, China. Aging (Albany NY). 2020; 13(2):1608-1619. DOI: 10.18632/aging.202261. PMID: 33318316Chen X., PengF, Zhou X., Zhu J., Chen X., Gong Y., Shupeng W., Niu W. Predicting severe or critical symptoms in hospitalized patients with COVID-19 from Yichang, China. Aging (Albany NY). 2020; 13 (2): 1608-1619. DOI: 10.18632/aging.202261. PMID: 33318316Kermali M., Khalsa R.K., Pillai K., Ismail Z., Harky A. The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci. 2020; 254:117788. DOI:10.1016/j.lfs.2020.117788. PMID: 32475810Kermali M., Khalsa R.K., Pillai K., Ismail Z., Harky A. The role of biomarkers in diagnosis of COVID-19 — A systematic review. Life Sci. 2020; 254: 117788. DOI: 10.1016/j.lfs.2020.117788. PMID: 32475810Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58(7):1021-1028. DOI: 10.1515/cclm-2020-0369. PMID: 32286245Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020; 58 (7): 10211028. DOI: 10.1515/cclm-2020-0369. PMID: 32286245Zheng Z., Peng F., Xu B., Zhao J., Liu H., Peng J., Li Q., Jiang C., Zhou Y., Liu S., Ye C., Zhang P., Xing Y., Guo H., Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81(2):e16-e25. DOI: 10.1016/j.jinf.2020.04.021. PMID: 32335169Zheng Z., Peng F, Xu B., Zhao J., Liu H., Peng J., Li Q., Jiang C., Zhou Y., Liu S., Ye C., ZhangP, Xing Y., Guo H., Tang W. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020; 81 (2): e16-e25. DOI: 10.1016/j.jinf.2020.04.021. PMID: 32335169Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P., Cockburn J., McDonald H.I., MacKenna B., Tomlinson L., Douglas I.J., Rentsch C.T., Mathur R., Wong A.Y.S., Grieve R., Harrison D., Forbes H., Schultze A., Croker R., Parry J., Hester F., Harper S., Perera R., Evans S.J.W., Smeeth L., Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584(7821):430-436. DOI: 10.1038/s41586-020-2521-4. PMID: 32640463Williamson E.J., Walker A.J., Bhaskaran K., Bacon S., Bates C., Morton C.E., Curtis H.J., Mehrkar A., Evans D., Inglesby P, Cockburn J., McDonald H.I., MacKennaB., TomlinsonL., DouglasI.J., Rentsch C.T., Mat-hur R., Wong AKS., Grieve R., Harrison D., Forbes H., Schultze A., Cro-ker R., Parry J., Hester F., Harper S., Perera R., Evans S.J.W., Smeeth L., Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020; 584 (7821): 430-436. DOI: 10.1038/s41586-020-2521-4. PMID: 32640463Foy B.H., Carlson J.C.T., Reinertsen E., Padros I Valls R., Pallares Lopez R., Palanques-Tost E., Mow C., Westover M.B., Aguirre A.D., Higgins J.M. Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection. JAMA Netw Open. 2020; 3(9):e2022058. DOI: 10.1001/jamanetworkopen.2020.22058. PMID: 32965501Foy B.H., Carlson J.C.T., Reinertsen E., Padros I Valls R., Pallares Lopez R., Palanques-Tost E., Mow C., Westover M.B., Aguirre A.D., Higgins J.M. Association of Red Blood Cell Distribution Width With Mortality Risk in Hospitalized Adults With SARS-CoV-2 Infection. JAMA Netw Open. 2020; 3 (9): e2022058. DOI: 10.1001/jamanetworkopen.2020.22058. PMID: 32965501Zhong Q., Peng J. Mean platelet volume/platelet count ratio predicts severe pneumonia of COVID-19. J Clin Lab Anal. 2021; 35(1):e23607. DOI: 10.1002/jcla.23607. PMID: 33128497Zhong Q., Peng J. Mean platelet volume/platelet count ratio predicts severe pneumonia of cOvID-19. JClin Lab Anal. 2021; 35 (1): e23607. DOI: 10.1002/jcla.23607. PMID: 33128497Ozen M., Yilmaz A., Cakmak V., Beyoglu R., Oskay A., Seyit M., Senol H. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021; 40:55-59. DOI: 10.1016/j.ajem.2020.12.023. PMID: 33348224Ozen M., Yilmaz A., Cakmak V, Beyoglu R., Oskay A., Seyit M., Senol H. D-Dimer as a potential biomarker for disease severity in COVID-19. Am J Emerg Med. 2021; 40: 55-59. DOI: 10.1016/j.ajem.2020.12.023. PMID: 33348224Lin J., Yan H., Chen H., He C., Lin C., He H., Zhang S., Shi S., Lin K. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. J Med Virol. 2021; 93(2):934-944. DOI: 10.1002/jmv.26346. PMID: 32706426Lin J., Yan H., Chen H., He C., Lin C., He H., Zhang S., Shi S., Lin K. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. J Med Virol. 2021; 93 (2): 934-944. DOI: 10.1002/jmv.26346. PMID: 32706426Liu Y., Du X., Chen J., Jin Y., Peng L., Wang H.H.X., Luo M., Chen L., Zhao Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81(1):e6-e12. DOI: 10.1016/j.jinf.2020.04.002. PMID: 32283162Liu Y., Du X., Chen J., Jin Y., Peng L., Wang H.H.X., Luo M., Chen L., Zhao Y. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020; 81 (1): e6-e12. DOI: 10.1016/j.jinf.2020.04.002. PMID: 32283162Kalemci S., Sarıhan A., Zeybek A. Association between NLR and COVID-19. Int Immunopharmacol. 2020; 88:106917. DOI: 10.1016/j.intimp.2020.106917. PMID: 32889243Kalemci S., Saryhan A., Zeybek A. Association between NLR and COVID-19. Int Immunopharmacol. 2020; 88: 106917. DOI: 10.1016/j.intimp.2020.106917. PMID: 32889243Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., Tian D.S. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71(15):762-768. DOI: 10.1093/cid/ciaa248. PMID: 32161940Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., WangW., TianD.S. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020; 71 (15): 762-768. DOI: 10.1093/cid/ciaa248. PMID: 32161940Yang A.P., Liu J.P., Tao W.Q., Li H.M. The diagnostic and predictive role of NLR, dNLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020; 84:106504. DOI: 10.1016/j.intimp.2020.106504. PMID: 32304994Yang A.P., Liu J.P., Tao W.Q., Li H.M. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharma-col. 2020; 84: 106504. DOI: 10.1016/j.intimp.2020.106504. PMID: 32304994Попов Д.А., Боровкова У.Л., Рыбка М.М., Рамненок Т.В., Голухова Е.З. Прогностическая ценность проадреномедуллина при COVID-19. Анестезиология и реаниматология. 2020;(6-2):6-12. DOI: 10.17116/anaesthesiology20200626.Popov D.A., Borovkova U.L., Rybka M.M., Ramnenok T.V., Golukhova E.Z. Predictive value of proadrenomedullin in patients with COVID-19. Anesteziol. iReanimatol.2020; (6-2): 6-12 [In Russ.]. DOI: 10.17116/anaesthesiology20200626Bertsimas D., Lukin G., Mingardi L., Nohadani O., Orfanoudaki A., Stellato B., Wiberg H., Gonzalez-Garcia S., Parra-Calderón C.L., Robinson K., Schneider M., Stein B., Estirado A., Beccara L., Canino R., Dal Bello M., Pezzetti F., Pan A.; Hellenic COVID-19 Study Group. COVID-19 mortality risk assessment: An international multicenter study. PLoS One. 2020; 15(12):e0243262. DOI: 10.1371/journal.pone.0243262. PMID: 33296405Bertsimas D., Lukin G., Mingardi L., Nohadani O., Orfanoudaki A., Stel-lato B., WibergH., Gonzalez-Garcia S., Parra-Calderon C.L., Robinson K., Schneider M., Stein B., Estirado A., Beccara L., Canino R., Dal Bello M., Pezzetti F., Pan A.; Hellenic COVID-19 Study Group. COVID-19 mortality risk assessment: An international multi-center study. PLoS One. 2020; 15 (12): e0243262. DOI: 10.1371/journal.pone.0243262. PMID: 33296405Ghayda R.A., Lee J., Lee J.Y., Kim D.K., Lee K.H., Hong S.H., Han Y.J., Kim J.S., Yang J.W., Kronbichler A., Smith L., Koyanagi A., Jacob L., Shin J.I. Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and MetaAnalysis. Int J Environ Res Public Health. 2020;17(14):5026. DOI: 10.3390/ijerph17145026. PMID: 32668763Ghayda R.A., Lee J., Lee J.Y., Kim D.K., Lee K.H., Hong S.H., Han Y.J., Kim J.S., Yang J.W., Kronbichler A., Smith L., Koyanagi A., Jacob L., Shin J.I. Correlations of Clinical and Laboratory Characteristics of COVID-19: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2020; 17 (14): 5026. DOI: 10.3390/ijerph17145026. PMID: 32668763Vieira F., Kung J.W., Bhatti F. Structure, genetics and function of the pulmonary associated surfactant proteins A and D: The extra-pulmonary role of these C type lectins. Ann Anat. 2017; 211:184-201. DOI:10.1016/j.aanat.2017.03.002Vieira F., KungJ.W., Bhatti F. Structure, genetics and function of the pulmonary associated surfactant proteins A and D: The extra-pulmonary role of these C type lectins. Ann Anat. 2017; 211: 184-201. DOI: 10.1016/j.aanat.2017.03.002Харламова О.С., Николаев К.Ю., Рагино Ю.И., Воевода М.И. Ассоциация белков сурфактанта SP-A и SP-D с тяжестью внебольничной пневмонии. Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2020; 9(3):348–355. DOI: 10.23934/2223-9022-2020-9-3-348-355.KharlamovaO.S.,NikolayevK.Y.,RaginoY.I.,VoyevodaM.I.Association of SP-A and SP-D Surfactant Proteins with the Severity of Communi-tyAcquired Pneumonia. Russian Sklifosovsky Journal«Emergency Medical Care». 2020; 9 (3): 348-355 [In Russ.]. DOI: 10.23934/2223-9022-2020-9-3-348-355Мороз В.В., Голубев А.М., Кузовлев А.Н., Писарев В.М., Шабанов А.К., Голубев М.А. Сурфактантный протеин D — биомаркер острого респираторного дистресссиндрома. Общая реаниматология. 2013;9(4):11. DOI: 10.15360/1813-9779-2013-4-11Moroz V.V., GolubevA.M., KuzovlevA.N., Pisarev V.M., ShabanovA.K., Golubev MA. Surfactant Protein D Is a Biomarker of Acute Respiratory Distress Syndrome. Obshchaya Reanimatologiya= General Reanima-tology. 2013; 9 (4): 11 [In Russ.]. DOI: 10.15360/1813-9779-2013-4-11Мороз В.В., Голубев А.М., Кузовлев А.Н., Писарев В.М., Половников С.Г., Шабанов А.К., Голубев М.А. Сурфактантный протеин А (SP-A) — прогностический молекулярный биомаркер при остром респираторном дистресс-синдроме. Общая реаниматология. 2013;9(3):5. DOI: 10.15360/1813-9779-2013-3-5Moroz W, Golubev A.M., Kuzo vlev A.N., Pisarev V.M., Polovnikov S.G., ShabanovA.K., Golubev M.A. Surfactant Protein A (SP-A) is a Prognostic Molecular Biomarker in Acute Respiratory Distress Syndrome. Obshchaya Reanimatologiya= General Reanimatology. 2013; 9 (3): 5 [In Russ.]. DOI: 10.15360/1813-9779-2013-3-5779-2013-3-5Dahmer M.K., Flori H., Sapru A., Kohne J., Weeks H.M., Curley M.A.Q., Matthay M.A., Quasney M.W.; BALI and RESTORE Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure. Chest. 2020; 158(3):1027-1035. DOI: 10.1016/j.chest.2020.03.041. PMID: 32275979Dahmer M.K., Flori H., Sapru A., Kohne J., Weeks H.M., Curley M.A.Q., Matthay M.A., Quasney M.W.; BALI and RESTORE Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Surfactant Protein D Is Associated With Severe Pediatric ARDS, Prolonged Ventilation, and Death in Children With Acute Respiratory Failure. Chest. 2020; 158 (3): 1027-1035. DOI: 10.1016/j.chest.2020.03.041. PMID: 32275979Jensen J.S., Itenov T.S., Thormar K.M., Hein L., Mohr T.T., Andersen M.H., Løken J., Tousi H., Lundgren B., Boesen H.C., Johansen M.E., Ostrowski S.R., Johansson P.I., Grarup J., Vestbo J., Lundgren J.D.; Procalcitonin And Survival Study (PASS) Group. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. Ann Intensive Care. 2016; 6(1):114. DOI: 10.1186/s13613-016-0212-y. PMID: 27873291Jensen J.S., Itenov T.S., Thormar K.M., Hein L., Mohr T.T., Andersen M.H., Loken J., Tousi H., Lundgren B., Boesen H.C., Johansen M.E., Ost-rowski S.R., Johansson PI., Grarup J., Vestbo J., Lundgren J.D.; Procalcitonin And Survival Study (PASS) Group. Prediction of non-recovery from ventilator-demanding acute respiratory failure, ARDS and death using lung damage biomarkers: data from a 1200-patient critical care randomized trial. Ann Intensive Care. 2016; 6 (1): 114. DOI: 10.1186/s13613-016-0212-y. PMID: 27873291Nayak A., Dodagatta-Marri E., Tsolaki A.G., Kishore U. An Insight into the Diverse Roles of Surfactant Proteins, SP-A and SP-D in Innate and Adaptive Immunity. Front Immunol. 2012;3:131. DOI:10.3389/fimmu.2012.00131. PMID: 22701116Nayak A., Dodagatta-Marri E., Tsolaki A.G., Kishore U. An Insight into the Diverse Roles of Surfactant Proteins, SP-A and SP-D in Innate and Adaptive Immunity. Front Immunol. 2012; 3: 131. DOI: 10.3389/fimmu.2012.00131. PMID: 22701116Al-Qahtani A.A., Murugaiah V., Bashir H.A., Pathan A.A., Abozaid S.M., Makarov E., Nal-Rogier B., Kishore U., Al-Ahdal M.N. Full-length human surfactant protein A inhibits influenza A virus infection of A549 lung epithelial cells: A recombinant form containing neck and lectin domains promotes infectivity. Immunobiology. 2019; 224(3):408-418. DOI: 10.1016/j.imbio.2019.02.006. PMID: 30954271Al-Qahtani A.A., Murugaiah V., Bashir H.A., Pathan A.A., Abozaid S.M., Makarov E., Nal-Rogier B., Kishore U., Al-Ahdal M.N. Full-length human surfactant protein A inhibits influenza A virus infection of A549 lung epithelial cells: A recombinant form containing neck and lectin domains promotes infectivity. Immunobiology. 2019; 224 (3): 408-418. DOI: 10.1016/j.imbio.2019.02.006. PMID: 30954271Harrod K.S., Trapnell B.C., Otake K., Korfhagen T.R., Whitsett J.A. SP-A enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am J Physiol. 1999; 277(3):L580-8. DOI: 10.1152/ajplung.1999.277.3.L580. PMID: 10484466HarrodK.S., TrapnellB.C., Otake K., Korfhagen T.R., WhitsettJ.A. SPA enhances viral clearance and inhibits inflammation after pulmonary adenoviral infection. Am J Physiol. 1999; 277 (3): L580-8. DOI: 10.1152/ajplung.1999.277.3.L580. PMID: 10484466van Iwaarden J.F., van Strijp J.A., Visser H., Haagsman H.P., Verhoef J., van Golde L.M. Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem. 1992; 267(35):25039-43. PMID: 1334078van Iwaarden J.F., van Strijp J.A., Visser H., Haagsman H.P., Verhoef J., van Golde L.M. Binding of surfactant protein A (SP-A) to herpes simplex virus type 1-infected cells is mediated by the carbohydrate moiety of SP-A. J Biol Chem. 1992; 267 (35): 25039-43. PMID: 1334078Broeckaert F., Bernard A.. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy. 2000; 30(4):469-75. DOI: 10.1046/j.1365-2222.2000.00760.x. PMID: 107188430Broeckaert F., Bernard A. Clara cell secretory protein (CC16): characteristics and perspectives as lung peripheral biomarker. Clin Exp Allergy. 2000; 30 (4): 469-75. DOI: 10.1046/j.1365-2222.2000.00760.x. PMID: 107188430Determann R.M., Millo J.L., Waddy S., Lutter R., Garrard C.S., Schultz M.J. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilatorassociated pneumonia: a retrospective observational study. BMC Pulm Med. 2009; 9:49. DOI:10.1186/1471-2466-9-49Determann R.M., Millo J.L., Waddy S., Lutter R., Garrard C.S., Schultz M.J. Plasma CC16 levels are associated with development of ALI/ARDS in patients with ventilator-associated pneumonia: a retrospective observational study. BMC Pulm Med. 2009; 9: 49. DOI: 10.1186/1471-2466-9-49Lin J, Zhang W, Wang L, Tian F. Diagnostic and prognostic values of Club cell protein 16 (CC16) in critical care patients with acute respiratory distress syndrome. J Clin Lab Anal. 2018; 32(2): e22262. DOI: 10.1002/jcla.22262. PMID: 28548310Lin J., Zhang W., Wang L., Tian F. Diagnostic and prognostic values of Club cell protein 16 (CC16) in critical care patients with acute respiratory distress syndrome. J Clin Lab Anal. 2018; 32 (2): e22262. DOI: 10.1002/jcla.22262. PMID: 28548310Johansson S., Kristjánsson S., Bjarnarson S.P., Wennergren G., Rudin A. Clara cell protein 16 (CC16) serum levels in infants during respiratory syncytial virus infection. Acta Paediatr. 2009; 98(3):579-81. DOI: 10.1111/j.1651-2227.2008.01083.x. PMID: 18976364Johansson S., Kristjansson S., Bjarnarson S.P., Wennergren G., Rudin A. Clara cell protein 16 (CC16) serum levels in infants during respiratory syncytial virus infection. Acta Paediatr. 2009; 98 (3): 579-81. DOI: 10.1111/j.1651-2227.2008.01083.x. PMID: 18976364Leth-Larsen R., Zhong F., Chow V.T., Holmskov U., Lu J. The SARS coronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology. 2007; 212(3):201-11. DOI: 10.1016/j.imbio.2006.12.001. PMID: 17412287Leth-Larsen R., Zhong F., Chow V.T., Holmskov U., Lu J. The SARS co-ronavirus spike glycoprotein is selectively recognized by lung surfactant protein D and activates macrophages. Immunobiology. 2007; 212 (3): 201-11. DOI: 10.1016/j.imbio.2006.12.001. PMID: 17412287Kerget B., Kerget F., Koçak A.O., Kızıltunç A., Araz Ö., Uçar E.Y., Akgün M. Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? Lung. 2020;198(5):777-784. DOI: 10.1007/s00408-020-00393-8. PMID: 32918573Kerget B., Kerget F., Kogak A.O., Kyzyltung A., Araz O., Ugar E.Y., Akgun M. Are Serum Interleukin 6 and Surfactant Protein D Levels Associated with the Clinical Course of COVID-19? Lung. 2020; 198 (5): 777784. DOI: 10.1007/s00408-020-00393-8. PMID: 32918573

The authors declare that there are no conflicts of interest present.